1.
Metabolism
; 103: 154031, 2020 02.
Article
in English
| MEDLINE
| ID: mdl-31785258
Subject(s)
Diabetes Mellitus/drug therapy , Drug Development/history , Hypoglycemic Agents/chemical synthesis , Incretins/pharmacology , Incretins/physiology , Biomedical Research/history , Diabetes Mellitus/epidemiology , Diabetes Mellitus/history , Drug Development/methods , Drug Industry/history , Drug-Related Side Effects and Adverse Reactions/epidemiology , History, 20th Century , History, 21st Century , Humans , Hypoglycemic Agents/history , Hypoglycemic Agents/therapeutic use , Incretins/history , Risk Assessment
2.
J Assoc Physicians India
; 65(4): 96, 2017 Apr.
Article
in English
| MEDLINE
| ID: mdl-28527176
3.
Nihon Rinsho
; 69(5): 755-60, 2011 May.
Article
in Japanese
| MEDLINE
| ID: mdl-21595258
ABSTRACT
'Incretin' hormones has lately attracted considerable attention as new strategy improving insulin secretion of type 2 diabetes mellitus. Spending many years for study of incretin hormones, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), we can use incretin mimetics as new drugs for type 2 diabetes clinically today in Japan. In this section, we describe the concept and the history of incretin hormones.
